DOCSLIB.ORG

Adenocarcinoma +++ ++ + Papillary Adenocarcinoma +++ ++ +

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adenocarcinoma +++ ++ + Papillary Adenocarcinoma +++ ++ + A Adenocarcinoma Total case no. +++ ++ + ─ Positive (%) HPC1 0 6 13 8 70.37 HPC2 1 2 9 15 44.44 27 HPC4 5 18 2 2 92.59 Con phage 0 0 0 27 0.00 Papillary adenocarcinoma Total case no. +++ ++ + ─ Positive (%) HPC1 2 1 3 2 75.00 HPC2 0 1 3 4 50.00 8 HPC4 1 5 1 1 87.50 Con phage 0 0 0 8 0.00 Bronchioloalveolar carcinoma Total case no. +++ ++ + ─ Positive (%) HPC1 2 4 1 1 87.50 HPC2 0 0 1 7 12.50 8 HPC4 1 5 1 1 87.50 Con phage 0 0 0 8 0.00 Squamous cell carcinoma Total case no. +++ ++ + ─ Positive (%) HPC1 5 7 12 3 88.89 HPC2 0 2 7 18 33.33 27 HPC4 9 16 1 1 96.30 Con phage 0 0 0 27 0.00 Large cell carcinoma Total case no. +++ ++ + ─ Positive (%) HPC1 0 6 3 1 90.00 HPC2 0 0 4 6 40.00 10 HPC4 5 4 0 1 90.00 Con phage 0 0 0 10 0.00 Small cell carcinoma Total case no. +++ ++ + ─ Positive (%) HPC1 2 5 1 0 100.00 HPC2 0 0 2 6 25.00 8 HPC4 5 3 0 0 100.00 Con phage 0 0 0 8 0.00 1 B Metastatic adenocarcinoma from lung Total case no. +++ ++ + ─ Positive (%) HPC1 0 1 6 1 87.50 HPC2 0 0 3 5 37.50 8 HPC4 2 4 2 0 100.00 Con phage 0 0 0 8 0.00 Metastatic squamous cell carcinoma from lung Total case no. +++ ++ + ─ Positive (%) HPC1 0 2 0 2 50.00 HPC2 0 0 1 3 25.00 4 HPC4 2 2 0 0 100.00 Con phage 0 0 0 4 0.00 C Normal pneumonic tissue Total case no. +++ ++ + ─ Positive (%) HPC1 0 0 0 6 0.00 HPC2 0 0 0 6 0.00 6 HPC4 0 0 0 6 0.00 Con phage 0 0 0 6 0.00 Cancer adjacent normal pneumonic tissue Total case no. +++ ++ + ─ Positive (%) HPC1 0 0 0 6 0.00 HPC2 0 0 0 6 0.00 6 HPC4 0 0 0 6 0.00 Con phage 0 0 0 6 0.00 2 Table S1. Clinical response rates in human lung cancer surgical specimens, as evidenced by immunohistochemistry (IHC) using HPC1, HPC2, and HPC4. (A) Several histopathological subtypes of clinical human lung cancer biopsies were immunostained by HPC1, HPC2, or HPC4, and compared to control phage. The positive response percentages were calculated and compiled. (B) IHC data for metastatic adenocarcinoma and SCC from lung. (C) Tumor specific binding of HPC1, HPC2, and HPC4 were examined using normal pneumonic tissue and cancer adjacent normal pneumonic tissue. Reaction area: +++, >50%; ++, 50~20%; +, <20%; －, 0%. 3 A Adenocarcinoma Grade Stage Type Con phageHPC1 HPC2 HPC4 AD1 1 T2N1M0 Malignant െ ++ െ +++ AD2 1 T2N1M0 Malignant െ + െ ++ AD3 1 T4NxM0 Malignant െ െ + + AD4 2 T2N1M0 Malignant െ ++ + +++ AD5 2 T1N0M0 Malignant െ ++ + ++ AD6 - T1N0M0 Malignant െ + െ +++ AD7 1 T3N1M0 Malignant െ + + ++ AD8 2 T1NxM0 Malignant െ + െ ++ AD9 1 TxN0M0 Malignant െ + െ ++ AD10 1 T4N1M0 Malignant െ + + ++ AD11 1 T1NxM0 Malignant െ െ െ ++ AD12 2 T4N2M0 Malignant െ െ + ++ AD13 2 T3N1M0 Malignant െ െ െ െ AD14 2 T3N1M0 Malignant െ െ െ െ AD15 2 T3N1M1 Malignant െ െ െ ++ AD16 3 T2N0M0 Malignant െ + ++ ++ AD17 2 T2N0M1 Malignant െ + +++ ++ AD18 2 T2N0M0 Malignant െ ++ െ ++ AD19 2 T2N0M0 Malignant െ + ++ +++ AD20 2 T2N1M0 Malignant െ െ + ++ AD21 3 T4NxM0 Malignant െ + െ ++ AD22 2 T3N0M0 Malignant െ + + ++ AD23 3 T4N0M0 Malignant െ ++ + +++ AD24 3 T3N0M0 Malignant െ െ െ ++ AD25 3 T1N0M0 Malignant െ ++ െ ++ AD26 3 T2N0M0 Malignant െ + െ ++ AD27 3 T2N0M0 Malignant െ + െ + 4 B Papillary adenocarcinoma Grade Stage Type Con phageHPC1 HPC2 HPC4 PAD1 1 T3N0M0 Malignant െ + + ++ PAD2 1 T2NxM0 Malignant െ + ++ +++ PAD3 2 T1N0M0 Malignant െ െ + ++ PAD4 2 T2N0M0 Malignant െ + + ++ PAD5 1 T1N0M0 Malignant െ െ െ െ PAD6 2 T1N0M0 Malignant െ +++ െ ++ PAD7 2 - 3 TxNxMx Malignant െ ++ െ + PAD8 2 T2N0M0 Malignant െ +++ െ ++ C Bronchioloalveolar carcinoma Grade Stage Type Con phageHPC1 HPC2 HPC4 BAC1 - T2N0M0 Malignant െ ++ െ ++ BAC2 - T3N0M0 Malignant െ ++ െ ++ BAC3 - T2N0M0 Malignant െ + െ ++ BAC4 - T2N0M0 Malignant െ +++ + ++ BAC5 - T2N0M0 Malignant െ ++ െ + BAC6 - T1N0M0 Malignant െ ++ െ +++ BAC7 - T2N0M0 Malignant െ െ െ െ BAC8 - TxNxMx Malignant െ +++ െ ++ 5 D Squamous cell carcinoma Grade Stage Type Con phageHPC1 HPC2 HPC4 SCC1 1 T2N0M0 Malignant െ ++ + +++ SCC2 1 T1NxM0 Malignant െ + െ ++ SCC3 1 T2N1M0 Malignant െ + ++ ++ SCC4 1 T2N3M0 Malignant െ + + ++ SCC5 1 T3N1M0 Malignant െ ++ + +++ SCC6 1 T2N1M0 Malignant െ + െ ++ SCC7 1 T2N1M0 Malignant െ ++ + +++ SCC8 1 T2NxM0 Malignant െ ++ െ +++ SCC9 1 T2N0M0 Malignant െ + െ +++ SCC10 1 T4NxM1 Malignant െ െ െ െ SCC11 1 T3N1M0 Malignant െ ++ െ ++ SCC12 2 T3N0M0 Malignant െ +++ + ++ SCC13 1 T3N1M0 Malignant െ + ++ +++ SCC14 2 T2N0M0 Malignant െ + െ ++ SCC15 2 T2N0M0 Malignant െ + െ ++ SCC16 2 T2N1M0 Malignant െ െ െ + SCC17 2 T3N3M0 Malignant െ + + ++ SCC18 3 T2N0M0 Malignant െ + െ ++ SCC19 2 T3N1M0 Malignant െ + െ ++ SCC20 2 T1N0M0 Malignant െ +++ െ ++ SCC21 3 T3NxM0 Malignant െ +++ െ ++ SCC22 3 T1N0M0 Malignant െ ++ െ +++ SCC23 3 T2N0M0 Malignant െ ++ െ +++ SCC24 3 T2N0M0 Malignant െ +++ െ +++ SCC25 3 T3N3M0 Malignant െ + െ ++ SCC26 3 T3N1M0 Malignant െ െ + ++ SCC27 3 T2N0M0 Malignant െ +++ െ ++ 6 E Large cell carcinoma Grade Stage Type Con phageHPC1 HPC2 HPC4 GCC1 - T2N0M0 Malignant െ ++ + +++ GCC2 - T3N0M0 Malignant െ ++ + +++ LCC1 - T3N0M0 Malignant െ ++ െ ++ LCC2 - T2NxM0 Malignant െ ++ + +++ LCC3 - T3N1M0 Malignant െ + െ ++ LCC4 - T2NxM0 Malignant െ + െ ++ LCC5 - T3NxM0 Malignant െ ++ + +++ LCC6 - T3N1M0 Malignant െ + െ ++ LCC7 - T2N0M0 Malignant െ ++ െ +++ LCC8 - T3NxM0 Malignant െ െ െ െ F Small cell carcinoma Grade Stage Type Con phageHPC1 HPC2 HPC4 SmCC1 - T3N1M0 Malignant െ +++ െ +++ SmCC2 - T3N2M0 Malignant െ + െ ++ SmCC3 - T2N1M0 Malignant െ ++ െ +++ SmCC4 - T3NxM0 Malignant െ ++ െ +++ SmCC5 - T2N1M0 Malignant െ ++ െ +++ SmCC6 - T3N0M0 Malignant െ ++ + +++ SmCC7 - T2N0M0 Malignant െ ++ െ ++ SmCC8 - T2N0M0 Malignant െ +++ + ++ 7 Table S2. Pathological diagnostic information of lung cancer stage and grade and their correlation to HPC1, HPC2, and HPC4 response rates. Reaction area: +++, >50%; ++, 50~20%; +, <20%; －, 0%. 8 A B Figure S1. In vitro phage display biopanning and selection of phage clones that bind to NSCLC cell lines. (A) A phage displayed random peptide library was used to select phages that bind to the lung large cell carcinoma cell line H460. (B) Forty-seven H460 bound phage clones with higher binding ability to NCI-H1993, CL1-5, A549, and 3LL cell lines were selected from the fifth round of biopanning for ELISA screening. Helper phage was used as a negative control. NNM was used as the normal cell control. 9 A B Figure S2. Predicted motifs and lung cancer cell line binding patterns of two major phage clone groups. (A) Binding intensity of HPC2, HPC3, HPC4, and HPC6 to H460, H1993, CL1-5, A549, and 3LL, as measured by ELISA of paraformaldehyde-fixed cells. The binding patterns of HPC3, HPC4, and HPC6 to these cell lines are similar, and distinct from those of HPC2. These data, combined with the observation that HPC4 exhibits better response rates in clinical biopsy and other cell-level experiments, suggest that the W-EMM mimetic motif plays a more important role than the NPW motif in human lung cancer binding. (B) HPC1, HPC12, HPC10, and HPC9 show similar binding patterns, suggesting that the MHL-W consensus sequence contributes to such binding. 10 A H460 H1993 FITC DAPI Merge FITC DAPI Merge HSP1-FITC HSP2-FITC HSP4-FITC ConP-FITC B Figure S3. Determination of binding specificity of FITC-labeled HSP1, HSP2, and HSP4 peptides to H460 and H1993 cells by immunofluorescent staining. (A) Immunofluorescent staining of FITC-labeled HSP1, HSP2, and HSP4 peptides to H460 large cell carcinoma and H1993 adenocarcinoma cell lines. Nuclei were stained with DAPI. Scale bar, 50 μm. (B) Table listing the percentage of IFA-positive cells for HSP1, HSP2, and HSP4-FITC in H460 and H1993 cell lines. 11 FITC DAPI Merge HSP1-FITC ScP1-FITC HSP2-FITC ScP2-FITC HSP4-FITC ScP4-FITC Figure S4. Scrambled peptides show no binding ability to H460 cells. Immunofluorescent staining of FITC-labeled scrambled peptides ScP1 (LGHPMATMWLGH), ScP2 (MYQEPSRWGENY), and ScP4 (IMEWNEYIMRPN) corresponding to HSP1, HSP2, and HSP4 for H460 binding. The nuclei were stained with DAPI. Scale bar, 20 μm. 12 Figure S5. A Large Cell Squamous Cell Small Cell Adenocarcinoma Carcinoma Carcinoma Carcinoma HPC2 HPC4 Con phage HPC1 B Pseudostratified Normal Normal Alveoli Columnar Bronchiole Epithelium HPC2 HPC4 Con phage HPC1 13 Figure S5. Immunohistochemical staining of human NSCLC, SCLC, and normal pneumonic tissues with HPC1, HPC2, and HPC4. Lower magnification (larger field of view) images, comparable to those shown in Figure 1B. (A) Serial sections of four subtypes of NSCLC and SCLC revealed prominent staining in tumor regions by HPC1 and HPC4, but weak or no signals in stroma regions. (B) Three histological types of tissue in normal lung did not cross-react with HPC1, HPC2, or HPC4. The same phage titer (2~5 × 108 pfu/μl) was used in each type of tissue. Helper phage was used as a negative control. Scale bar, 100 μm. 14 Figure S6. Phage distribution of the liver, kidney, and spleen in tumor-homing experiments. Although there was a noticeable uptake of phage by the organs of mononuclear phagocyte system such as the liver and spleen, no significant difference in accumulation between the targeting and control phages was observed in these organs. 15 Figure S7. In vitro cell binding of targeting SPIONs. Prussian blue staining of fixed H460 cells treated with HSP1-, HSP2-, HSP4-, Ctrl P-Dex- Fe3O4,orDex-Fe3O4 nanoparticles (10 μg/ml) for 1 hr. 16 Figure S8. HSP1, HSP2, and HSP4 peptides enhance LSRB in a human lung cancer cell line, H460. Kinetics of HSP1-LSRB, HSP2-LSRB, HSP4-LSRB, and LSRB uptake by H460 cells at 37°C. After washing with acid glycine buffer to remove surface-bound liposomal dye, internalized SRB was quantified (n=4). 17 A B Figure S9. HSP1, HSP2, and HSP4 peptides enhance LSRB internalization and LD uptake in a human lung adenocarcinoma cell line, H1993. (A) Uptake kinetics of non-targeting LSRB and peptide (HSP1, HSP2, and HSP4)- conjugated LSRB by H1993 cells at 37°C. After washing with acid glycine buffer to remove surface-bound liposomal dye, internalized SRB was quantified (n=4). These results indicate that HSP4 is most effective at triggering endocytosis in the H1993 adenocarcinoma cell line from low to high concentrations; notably, this kinetic pattern is distinct from that observed using H460 large cell carcinoma cell lines (Figure S8).
Load more

Recommended publications
  • Lung Equivalent Terms, Definitions, Charts, Tables and Illustrations C340-C349 (Excludes Lymphoma and Leukemia M9590-9989 and Kaposi Sarcoma M9140)
    Lung Equivalent Terms, Definitions, Charts, Tables and Illustrations C340-C349 (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140) Introduction Use these rules only for cases with primary lung cancer. Lung carcinomas may be broadly grouped into two categories, small cell and non-small cell carcinoma. Frequently a patient may have two or more tumors in one lung and may have one or more tumors in the contralateral lung. The physician may biopsy only one of the tumors. Code the case as a single primary (See Rule M1, Note 2) unless one of the tumors is proven to be a different histology. It is irrelevant whether the other tumors are identified as cancer, primary tumors, or metastases. Equivalent or Equal Terms • Low grade neuroendocrine carcinoma, carcinoid • Tumor, mass, lesion, neoplasm (for multiple primary and histology coding rules only) • Type, subtype, predominantly, with features of, major, or with ___differentiation Obsolete Terms for Small Cell Carcinoma (Terms that are no longer recognized) • Intermediate cell carcinoma (8044) • Mixed small cell/large cell carcinoma (8045) (Code is still used; however current accepted terminology is combined small cell carcinoma) • Oat cell carcinoma (8042) • Small cell anaplastic carcinoma (No ICD-O-3 code) • Undifferentiated small cell carcinoma (No ICD-O-3 code) Definitions Adenocarcinoma with mixed subtypes (8255): A mixture of two or more of the subtypes of adenocarcinoma such as acinar, papillary, bronchoalveolar, or solid with mucin formation. Adenosquamous carcinoma (8560): A single histology in a single tumor composed of both squamous cell carcinoma and adenocarcinoma. Bilateral lung cancer: This phrase simply means that there is at least one malignancy in the right lung and at least one malignancy in the left lung.
    [Show full text]
  • Mixed Squamous Cell and Glandular Papilloma Presented with Peripheral Lung Mass: a Case Report
    J Lung Cancer 2012;11(2):94-96 http://dx.doi.org/10.6058/jlc.2012.11.2.94 Mixed Squamous Cell and Glandular Papilloma Presented with Peripheral Lung Mass: A Case Report Mixed squamous cell and glandular papilloma is a rare pulmonary neoplasm Si-Hyong Jang, M.D.1 2 typically occurring in the central lung area. Herein, we report a case of Tae Sung Kim, M.D., Ph.D. 3 peripherally located mixed papilloma in a 54-year-old man with a complaint Jae Ill Zo, M.D., Ph.D. and Joungho Han, M.D., Ph.D.1 of dyspnea. Chest computed tomography demonstrated an infiltrative peri- pheral lung mass in the right middle lobe, measuring 1.5 cm in diameter. Departments of 1Pathology, 2Radiology, The resected lung tumor had papillary configuration lined by both squamous and 3Thoracic Surgery, Sungkyun- cell epithelium and mucin-containing glandular epithelium. The papillary kwan University School of Medicine, Seoul, Korea stroma showed a fibrovascular core with inflammatory infiltrates. p63 immunostaining was positive in basal and parabasal tumor cells in papillary Received: June 11, 2012 fronds. (J Lung Cancer 2012;11(2):94 96) Revised: August 29, 2012 Accepted: August 30, 2012 Address for correspondence Joungho Han, M.D., Ph.D. Department of Pathology, Samsung Medical Center, Sungkyunkwan Uni- versity School of Medicine, 50, Irwon- dong, Gangnam-gu, Seoul 135-710, Korea Tel: 82-2-3410-2800 Fax: 82-2-3410-0025 Key Words: Lung, Neoplasms, Papilloma E-mail: [email protected] Solitary respiratory papilloma is an unusual benign neoplasm history and laboratory studies were unremarkable.
    [Show full text]
  • Peritoneal Serous Papillary Adenocarcinoma: Report of Four Cases
    □ CASE REPORT □ Peritoneal Serous Papillary Adenocarcinoma: Report of Four Cases Takeshi MINAMI, Koji NAKATANI, Shinya KONDO, Shuji KANAYAMA and Takahiro TSUJIMURA* Abstract Case Reports We report four cases of peritoneal serous papillary Case 1 adenocarcinoma (PSPC), a rare disease; all patients had A 71-year-old woman visited Sumitomo hospital com- ascites and high levels of serum CA125. Clinical and plaining of abdominal distention and was admitted in radiological examinations could not differentiate the February 1989 because of massive ascites. From laboratory disease from peritoneal metastatic tumors and mesothe- data, anemia (Hb 9.2 mg/dl) and a high level of serum lioma, and histopathological analysis including immuno- CA125 (10,330 U/ml) were seen. Abdominal CT revealed a chemistry on the specimen obtained at laparotomy or poorly defined hazy mass in the anterior portion of the peri- laparoscopy was necessary for the diagnosis. One patient toneal cavity with retroperitoneal lymphadenopathy, omental lived for 58 months with cytoreductive surgery and caking appearance, and ascites. Gynecological survey, and chemotherapy, and another is still living after 20 months endoscopic examinations of the upper gastrointestinal tract by chemotherapy alone. In patients with peritoneal tumors and colon did not reveal neoplastic lesions. Because of unknown origin and a high level of serum CA125, tak- adenocarcinoma cells were found in the ascites specimen on ing PSPC into consideration in the differential diagnosis, cytologic examination, intraperitoneal injection of cisplatin histopathological examination should be performed. was started. Then, the ascites and the serum CA125 levels (Internal Medicine 44: 944–948, 2005) decreased. On the 66th hospital day, she complained of sud- den abdominal pain, and free air was intraperitonally ob- Key words: peritoneum, chemotherapy, immunohistochemi- served on abdominal X-P.
    [Show full text]
  • Sinonasal Tumors
    Prepared by Kurt Schaberg Sinonasal/Nasopharyngeal Tumors Benign Sinonasal Papillomas aka Schneiderian papilloma Morphology Location Risk of Molecular transformation Exophytic Exophytic growth; Nasal Very low risk Low-risk HPV immature squamous epithelium septum subtypes Inverted Inverted ‘‘ribbonlike’’ growth; Lateral Low to EGFR immature squamous epithelium; wall and Intermediate risk mutations or transmigrating intraepithelial sinuses low-risk HPV neutrophilic inflammation subtypes Oncocytic Exophytic and endophytic growth; Lateral Low to KRAS multilayered oncocytic epithelium; wall and intermediate microcysts and intraepithelial sinuses neutrophilic microabscesses Modified from: Weindorf et al. Arch Pathol Lab Med—Vol 143, November 2019 Oncocytic Sinonasal Papilloma Note the abundant oncocytic epithelium with numerous neutrophils Inverted Sinonasal Papilloma Note the inverted, “ribbon-like” growth Respiratory Epithelial Adenomatoid Hamartoma aka “REAH” Sinonasal glandular proliferation arising from the surface epithelium (i.e., in continuity with the surface). Invaginations of small to medium-sized glands surrounded by hyalinized stroma with characteristic thickened, eosinophilic basement membrane Exists on a spectrum with seromucinous hamartoma, which has smaller glands. Should be able to draw a circle around all of the glands though, if too confluent → consider a low-grade adenocarcinoma Inflammatory Polyp Surface ciliated, sinonasal mucosa, possibly with squamous metaplasia. Edematous stroma (without a proliferation of seromucinous glands). Mixed inflammation (usu. Lymphocytes, plasma cells, and eosinophils) Pituitary adenoma Benign anterior pituitary tumor Although usually primary to sphenoid bone, can erode into nasopharynx or be ectopic Can result in endocrine disorders, such as Cushing’s disease or acromegaly. Solid, nested, or trabecular growth of epithelioid cells with round nuclei and speckled chromatin and eosinophilic, granular chromatin. Express CK, and neuroendocrine markers.
    [Show full text]
  • Well Differentiated Papillary Mesothelioma of Abdomen‑ a Rare Case with Diagnostic Dilemma
    Published online: 2020-02-19 Case Report Access this article online Quick Response Code: Well differentiated papillary mesothelioma of abdomen‑ a rare case with diagnostic dilemma Aniruddha Saha, Palash Kumar Mandal1, Anupam Manna, Kalyan Khan2, Subrata Pal1 Website: www.jlponline.org Abstract: DOI: 10.4103/JLP.JLP_167_16 Well-differentiated papillary mesothelioma is a rare tumor occurring predominantly in the peritoneum of young women, a few with history of asbestos exposure. A 28-year-old woman presented with ascites and pain abdomen. Ultrasonography and computed tomography scan of the abdomen revealed a mass in the retroperitoneum measuring 15 cm × 12 cm. Histopathological examination along with immunohistochemistry (IHC) confirmed it to be a papillary mesothelioma in the peritoneum. It is difficult to differentiate from more common malignant mesothelioma and papillary adenocarcinoma, which also have poorer prognosis. The difficulty can be resolved by clinico-radiological correlation along with histopathological examination and IHC. Key words: Immunohistochemistry, peritoneum, well-differentiated papillary mesothelioma Introduction The ultrasonography of whole abdomen showed an abdomino‑pelvic mass along ell‑differentiated papillary with ascites. Ascitic fluid examination was Wmesotheliomas (WDPMs) of the done and showed few cellular fragments of peritoneum are uncommon; approximately mesothelial cells admixed with lymphocytes. 50 cases have been reported till date.[1‑5] Abdominal computed tomography (CT) Approximately 75% of the tumors occurred scan showed mass measuring 14 cm × 11 cm, in females who are usually of reproductive but the site of origin could not be identified age but occasionally postmenopausal.[2] and possibility of the left adnexal mass was WDPM is usually an incidental finding at suggested [Figure 1a].
    [Show full text]
  • Concurrent Squamous‑Cell Carcinoma Esophagus and Atypical Carcinoid Tumor: a Rare Case Report and Review of Literature
    Published online: 2021-06-03 Letter to Editor Concurrent Squamous‑Cell Carcinoma Esophagus and Atypical Carcinoid Tumor: A Rare Case Report and Review of Literature Sir, syndrome. Follow‑up PET‑CT was normal, and hence the Carcinoma esophagus is very common malignancy which patient was kept on close follow‑up, but at the time of is usually managed with chemoradiation or chemoradiation writing the paper, the patient was untraceable. plus surgery and squamous cell and adenocarcinoma are Carcinoma esophagus with neuroendocrine carcinoma is the two most common types. Very rarely, we can have a very rare entity. There are two types of mixed tumors, neuroendocrine carcinoma or tumor of the esophagus. Here, namely, collision and composite. Collision tumor is we are presenting a very rare, probably first such case of composed of two independent tumors growing very closely, concurrent squamous‑cell carcinoma of the esophagus which subsequently collide with each other, ultimately along with atypical carcinoid tumor which was incidentally forming a single mass. The cells of origin are different, detected in residual node postchemoradiation and surgery. and histopathology too shows clear demarcation between A 52 year‑old nonsmoker, alcoholic male patient with the two tumors.[1] The second type is composite tumors spinocerebellar ataxia as comorbidity, presented in November in which one neoplastic clone diverges into different 2016, with a complaint of progressive dysphagia of cell lineages. The origin is from one single pluripotent 2 months duration. Upper gastrointestinal endoscopy showed stem cell.[2] Histopathology, IHC analysis, microsatellite circumferential growth in lower‑third of the esophagus instability testing, and electron microscopy can help with luminal narrowing.
    [Show full text]
  • Head and Neck Pathology
    316A ANNUAL MEETING ABSTRACTS Results: IPMC involved >5% of villi in 11 of 17 placentas (65%) from FD cases, but Immunohistochemical study showed consistent loss of PAX2 nuclear staining in 100% only 1 of 118 from live births (0.8%, p<0.0001). IPMC involved >10% of villi in 5 of cases regardless of endocervical-type or gastrointestinal-type. All cases showed positive 17 placentas (30%) from FD cases and none from live births (0%, p<0.0001). Clinical PAX8 staining and wild-type p53 staining pattern including those of gastrointestinal data for 11 of the 17 FD cases was available. IPMC in >5% of villi were seen in 3 of type. ER was diffuse (>70%) and strong in eleven cases (85%), focal and moderate the 7 cases where fetus was delivered within 1 day, versus 4 of 4 cases where fetus in two cases. PR was negative in six cases, focal and moderate in four cases, diffuse was retained for >1 days after demise (p<.05). Frequency of IPMC in categories other and strong (>70%) in three cases. P16 was either negative (5) or focally positive (8). than fetal demise are shown in table 1. Conclusions: Pure EMC is diagnostically challenging due to its bland histologic features. Our study demonstrates that loss of PAX2 staining was observed in all cases Percentage of Post Term IUGR Chronic Chorioamnionitis GDM (n=20), regardless of endocervical or gastrointestinal cell type. Retaining strong ER expression Villi involved Births (n=15), Villitis (n=19), n(%) n(%) by IPMC (%) (n=12), n(%) n(%) (n=15), n(%) and variable loss of PR expression occurred in most pure EMC (77%).
    [Show full text]
  • 2018 Solid Tumor Rules Lois Dickie, CTR, Carol Johnson, BS, CTR (Retired), Suzanne Adams, BS, CTR, Serban Negoita, MD, Phd
    Solid Tumor Rules Effective with Cases Diagnosed 1/1/2018 and Forward Updated November 2020 Editors: Lois Dickie, CTR, NCI SEER Carol Hahn Johnson, BS, CTR (Retired), Consultant Suzanne Adams, BS, CTR (IMS, Inc.) Serban Negoita, MD, PhD, CTR, NCI SEER Suggested citation: Dickie, L., Johnson, CH., Adams, S., Negoita, S. (November 2020). Solid Tumor Rules. National Cancer Institute, Rockville, MD 20850. Solid Tumor Rules 2018 Preface (Excludes lymphoma and leukemia M9590 – M9992) In Appreciation NCI SEER gratefully acknowledges the dedicated work of Dr. Charles Platz who has been with the project since the inception of the 2007 Multiple Primary and Histology Coding Rules. We appreciate the support he continues to provide for the Solid Tumor Rules. The quality of the Solid Tumor Rules directly relates to his commitment. NCI SEER would also like to acknowledge the Solid Tumor Work Group who provided input on the manual. Their contributions are greatly appreciated. Peggy Adamo, NCI SEER Elizabeth Ramirez, New Mexico/SEER Theresa Anderson, Canada Monika Rivera, New York Mari Carlos, USC/SEER Jennifer Ruhl, NCI SEER Louanne Currence, Missouri Nancy Santos, Connecticut/SEER Frances Ross, Kentucky/SEER Kacey Wigren, Utah/SEER Raymundo Elido, Hawaii/SEER Carolyn Callaghan, Seattle/SEER Jim Hofferkamp, NAACCR Shawky Matta, California/SEER Meichin Hsieh, Louisiana/SEER Mignon Dryden, California/SEER Carol Kruchko, CBTRUS Linda O’Brien, Alaska/SEER Bobbi Matt, Iowa/SEER Mary Brandt, California/SEER Pamela Moats, West Virginia Sarah Manson, CDC Patrick Nicolin, Detroit/SEER Lynda Douglas, CDC Cathy Phillips, Connecticut/SEER Angela Martin, NAACCR Solid Tumor Rules 2 Updated November 2020 Solid Tumor Rules 2018 Preface (Excludes lymphoma and leukemia M9590 – M9992) The 2018 Solid Tumor Rules Lois Dickie, CTR, Carol Johnson, BS, CTR (Retired), Suzanne Adams, BS, CTR, Serban Negoita, MD, PhD Preface The 2007 Multiple Primary and Histology (MPH) Coding Rules have been revised and are now referred to as 2018 Solid Tumor Rules.
    [Show full text]
  • A Rare Case of Well Differentiated Papillary Mesothelioma of Peritoneal Origin
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861. Volume 6, Issue 5 (May.- Jun. 2013), PP 01-04 www.iosrjournals.org A Rare Case Of Well Differentiated Papillary Mesothelioma Of Peritoneal Origin Dr. B. Anil Kumar1, Professor, Dr. Sajana Gogineni2, Professor, Dr. Channareddy Suneetha3, Assistant. Professor, Dr. Kalyan Chakravarthy4, Professor, Dr. B. Nissy Jacintha5, PG 1(Dept. of General Surgery, Dr. PSIMS & RF, Chinoutpalli, AP, India) 2,3,5(Dept. of OBG, Dr. PSIMS & RF, Chinoutpalli, AP, India) 4(Dept. of Pathology, Dr. PSIMS & RF, Chinoutpalli, AP, India Abstract: Solitary well differentiated papillary mesothelioma is an unusual variant of epithelial mesothelioma. Most of them exhibit either benign or indolent behavior. Making the differential diagnosis between this rare tumor and serous papillary carcinoma can be problematic. We report here a case of a 24 year-old unmarried female with a well differentiated papillary mesothelioma of peritoneal origin. Key Words: Mesothelioma ; Ovary; well differentiated papillary mesothelioma. I. Introduction Well differentiated papillary mesothelioma (WDPM) is an unusual variant of epithelial mesothelioma. It occurs mainly in the peritoneum, and this tumor is most commonly seen in young women who have no history of asbestos exposure. It is often found incidentally at laparotomy that is done for other indications.1,2 WDPM rarely occurs at other sites, including the ovary,3,4 pericardium, 5 and the tunica vaginalis.6,7 The tumor is occasionally found on as a frozen sectioning because surgeons suspect this tumor to be other malignant tumors, such as diffuse malignant mesothelioma, or peritoneal dissemination from other tumor sites or ovarian serous papillary carcinoma.1 Most WDPMs exhibit either a benign or indolent behavior.1-8 Making the differential diagnosis between this rare tumor and serous papillary carcinoma can be problematic.
    [Show full text]
  • The Diagnostic Utility of Immunohistochemistry and Electron Microscopy in Distinguishing Between Peritoneal Mesotheliomas and Serous Carcinomas: a Comparative Study
    Modern Pathology (2006) 19, 34–48 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study Nelson G Ordo´n˜ ez Department of Pathology, MD Anderson Cancer Center, The University of Texas, TX, USA The histologic distinction between peritoneal epithelioid mesotheliomas and serous carcinomas diffusely involving the peritoneum may be difficult, but it can be facilitated by the use of immunohistochemistry and electron microscopy. D2-40 and podoplanin are two recently recognized lymphatic endothelial markers that can be expressed in normal mesothelial cells and mesotheliomas. The purpose of this study is to compare the value of these new mesothelial markers with those that are commonly used for discriminating between mesotheliomas and serous carcinomas, and also to determine the current role of electron microscopy in distinguishing between these malignancies. A total of 40 peritoneal epithelioid mesotheliomas and 45 serous carcinomas of the ovary (15 primary, 30 metastatic to the peritoneum) were investigated for the expression of the following markers: D2-40, podoplanin, calretinin, keratin 5/6, thrombomodulin, MOC-31, Ber-EP4, B72.3 (TAG-72), BG-8 (LewisY), CA19-9, and leu-M1 (CD15). All 40 (100%) of the mesotheliomas reacted for calretinin, 93% for D2-40, 93% for podoplanin, 93% for keratin 5/6, 73% for thrombomodulin, 13% for Ber-EP4, 5% for MOC- 31, 3% for BG-8, and none for B72.3, CA19-9, or leu-M1. All 45 (100%) serous carcinomas were positive for Ber-EP4, 98% for MOC-31, 73% for B72.3, 73% for BG-8, 67% for CA19-9, 58% for leu-M1, 31% for keratin 5/6, 31% for calretinin, 13% for D2-40, 13% for podoplanin, and 4% for thrombomodulin.
    [Show full text]
  • Papillary Adenocarcinoma of the Lung. Case Report of Uncommon Tumor
    SM Journal of Pulmonary Medicine ISSN: 2574-240X Case Report © Sheplay K. et al. 2021 Papillary Adenocarcinoma of the Lung. Case Report of Uncommon Tumor and Review of the Literature Kirk Sheplay*, Jacqueline Nicholas, Aimee Lombard, Carly Funk, Jordan Stone, Viviana Crespo and Mohamed Aziz Department of Pathology, American University of the Caribbean, School of Medicine, USA Abstract Based on the new 2015 WHO classification of lung tumors, invasive adenocarcinomas with multiple different patterns should no longer be classified as “mixed adenocarcinoma”, and each subtype must be assessed and reported semi-quantitatively (in 5% increments). Papillary adenocarcinoma (PA) is a subtype of invasive adenocarcinoma defined by presence of papillary structures with true fibrovascular cores replacing the alveolar lining or present within the alveolar spaces. Pure lung papillary adenocarcinoma represents about 7.4-12% of lung adenocarcinomas. We report a case of papillary lung adenocarcinoma presenting as a small solitary nodule, and we discuss diagnostic features, differential diagnosis, molecular changes, treatment, and prognosis. Keywords: Papillary, Micropapillary, Adenocarcinoma, Differential diagnosis, Molecular ABBREVIATION treatment modalities (2). We present an uncommon case of PA. PA: Papillary adenocarcinoma, CECT: Contrast enhanced prognosis and cytogenetic abnormalities, demanding specific computed tomography, IHC: Immunohistochemistry, BAC: CASE PRESENTATION Bronchoalveolar carcinoma A 37-year-old woman presented with cough and chest INTRODUCTION pain. Patient was a non-smoker with no other risk factors for Primary Papillary Adenocarcinoma (PA), is an uncommon left lung tumor mass. Contrast enhanced computed tomography invasive subtype of adenocarcinoma of the lung with a thoraxmalignancy. (CECT) Chest revealed X-ray showeda mass lesion a small measuring poorly defined 1.8 cm infiltrating x 1.2 cm predominance of papillary structures that replace the underlying in the left lower lobe of the lung.
    [Show full text]
  • Adopted Regulation of the State Board of Health Lcb
    ADOPTED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R075-98 Effective November 18, 1998 EXPLANATION – Matter in italics is new; matter in brackets [ ] is material to be omitted. AUTHORITY: §§ 2-13, NRS 439.200, 457.065 and 457.240; § 14, NRS 439.200 and 457.065 Section 1. Chapter 457 of NAC is hereby amended by adding thereto the provisions set forth as sections 2, 3 and 4 of this regulation. Sec. 2. 1. A medical laboratory that obtains a specimen of human tissue which, upon examination, shows evidence of cancer shall, within 10 working days after the date that the pathology report is completed, provide information concerning its findings to the state health officer using an electronic means approved by the state health officer or his designee. 2. The information provided by a medical laboratory pursuant to subsection 1 must include, without limitation: (a) The name, address, date of birth, gender and social security number of the person from whom the specimen was obtained; (b) The name and the address or telephone number of the physician who ordered the examination of the specimen; (c) The name and the address or telephone number of the medical laboratory that examined the specimen; (d) The final diagnosis from the pathology report; and --1-- Adopted Regulation R075-98 (e) Any other relevant information from the pathology report, including, without limitation: (1) The anatomical site of the lesion; (2) The size of the lesion; (3) The stage of the disease and the grade of tumor; (4) The lesion margin status, if available; and (5) Lymphatic involvement, if available.
    [Show full text]